Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 4Endometrial Neoplasms 3Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 6Nivolumab 3Cisplatin 3Carboplatin 3Paclitaxel 2Fluorouracil 2tucatinib 1pertuzumab 1milademetan 1lenvatinib 1cemiplimab 1Trastuzumab 1Tomography, X-Ray Computed 1Ritonavir 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Magnetic Resonance Imaging 1Leucovorin 1Itraconazole 1Gemcitabine 1Fulvestrant 1Cetuximab 1Capecitabine 1Brachytherapy 1Bevacizumab 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × AZD5305 × Gynecologic × Clear all
NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡